{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:31:59Z","timestamp":1768386719557,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jcf.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:50:40Z","timestamp":1763625040000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3616-3595","authenticated-orcid":false,"given":"Nazanin","family":"Abolhassani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-3435","authenticated-orcid":false,"given":"Kim","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-7926","authenticated-orcid":false,"given":"Roberta","family":"Noseda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8584-7408","authenticated-orcid":false,"given":"Francesca","family":"Bedussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4308-0405","authenticated-orcid":false,"given":"Alessandro","family":"Ceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6086-2401","authenticated-orcid":false,"given":"Alice","family":"Panchaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9926-7164","authenticated-orcid":false,"given":"Ursula","family":"Winterfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0001","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jcf.2025.02.012","article-title":"Cystic fibrosis year in review 2024","volume":"24","author":"Alameeri","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jcf.2025.03.002","article-title":"CFTR modulators and pregnancy outcomes: early findings from a nationwide cohort study","volume":"24","author":"Chouchana","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.007_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.06.001","article-title":"Pregnancy and neonatal outcome following in utero exposure to CFTR modulators: a multicentre prospective case series","author":"Gautier","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.007_bib0004","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcf.2015.11.013","article-title":"A successful uncomplicated CF pregnancy while remaining on Ivacaftor","volume":"15","author":"Kaminski","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jogn.2016.08.011","article-title":"A case report of pregnancy during use of targeted therapeutics for cystic fibrosis","volume":"46","author":"Ladores","year":"2017","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jcf.2018.05.009","article-title":"Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding","volume":"17","author":"Trimble","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2020.02.018","article-title":"Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators - an international survey","volume":"19","author":"Nash","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0008","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/archdischild-2024-327678","article-title":"Use of CFTR modulators in pregnancy: new information for neonatal, paediatrics and midwifery teams","volume":"110","author":"Khan","year":"2025","journal-title":"Archiv Disease Childhood Fetal Neonatal Edition"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0009","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.chest.2024.09.019","article-title":"Impact of cystic fibrosis transmembrane conductance regulator modulators on maternal outcomes during and after pregnancy","volume":"167","author":"Jain","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2025.11.007_bib0010","unstructured":"Trikafta(R) SmPC. Swissmedicinfo [Available from: https:\/\/swissmedicinfo.ch\/ViewMonographie#section15. 2025."},{"issue":"6","key":"10.1016\/j.jcf.2025.11.007_bib0011","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.007_bib0012","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jcf.2025.11.007_bib0014","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0015","doi-asserted-by":"crossref","first-page":"e2314","DOI":"10.1002\/bdr2.2314","article-title":"Updated EUROCAT guidelines for classification of cases with congenital anomalies","volume":"116","author":"Bergman","year":"2024","journal-title":"Birth Defects Res"},{"issue":"11","key":"10.1016\/j.jcf.2025.11.007_bib0016","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40264-024-01448-y","article-title":"Identification of pregnancy adverse drug reactions in pharmacovigilance reporting systems: a novel algorithm developed in eudravigilance","volume":"47","author":"Zaccaria","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.jcf.2025.11.007_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"issue":"10","key":"10.1016\/j.jcf.2025.11.007_bib0018","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","article-title":"Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase","volume":"43","author":"Sandberg","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.007_bib0019","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in Pharmacovigilance (READUS-PV): development and Statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.007_bib0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.007_bib0021","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ije\/dyz009","article-title":"Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies","volume":"48","author":"Liu","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.007_bib0022","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1097\/AOG.0000000000002899","article-title":"American College of O, Gynecologists' Committee on Practice B-G. ACOG Practice Bulletin No. 200: early Pregnancy Loss","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.007_bib0023","first-page":"809","article-title":"Cystic fibrosis in pregnancy","volume":"149","author":"Kent","year":"1993","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.jcf.2025.11.007_bib0024","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/1471-0528.16957","article-title":"Pregnancy rates and outcomes in women with cystic fibrosis in the UK: comparisons with the general population before and after the introduction of disease-modifying treatment, 2003-17","volume":"129","author":"Esan","year":"2022","journal-title":"BJOG"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.007_bib0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jcf.2019.06.003","article-title":"Pregnancy outcome in women with cystic fibrosis and poor pulmonary function","volume":"19","author":"Reynaud","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2007.10.001","article-title":"Guidelines for the management of pregnancy in women with cystic fibrosis","volume":"7","author":"Edenborough","year":"2008","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T04:35:26Z","timestamp":1768365326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1569199325025032"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CFTR during pregnancy and adverse drug reactions: A pharmacovigilance disproportionality analysis in VigiBase","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}